POST Online Media Lite Edition


Sequenom names Paul Maier interim chief financial officer

Staff writer |
San Diego, Ca.,USA - October 27, 2009, San Diego, Ca.,USA - Sequenom, a life sciences company, announced that Paul V. Maier has been appointed as the company's interim chief financial officer, effective November 10.

Article continues below

Prior to the effective date of Mr. Maier's appointment as interim chief financial officer, Mr. Maier will act as a consultant to the company. Mr. Maier has been an independent financial consultant since February 2007. Mr. Maier served as senior vice president and chief financial officer of Ligand Pharmaceuticals Incorporated from 1992 until January 2007, where he helped build Ligand from a venture stage boutique company to a commercial, integrated biopharmaceutical organization. During his tenure at Ligand, Mr. Maier helped raise over $1 billion in equity and debt financings. Prior to Ligand, Mr. Maier spent six years in various management and finance positions at ICN Pharmaceutic


Boot Barn Holdings appoints two to board
LeapFrog appoints Joanna Rees to board
New Resource Bank appoints two new directors
Havok: Brian Waddle VP of worldwide sales and marketing
Teleplace: Stephen Ceplenski new senior vice president

What to read next

Apricus Bio appoints Paul V. Maier to the board
NovaBay Pharmaceuticals announces resignation of board member
Paul Maier joins NACR and S1 IT as SVP, president